National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 12 of 1998)

Overview

The National Health Act 1953 was enacted to establish and promote the national health scheme in Australia, addressing the gap in providing a coordinated and comprehensive approach to health services. This Act, enacted by the Commonwealth Parliament, aims to ensure the availability and affordability of essential health services, including pharmaceuticals, to the Australian public. This legislative instrument, F2007B01104, is a declaration made under subsection 85(2AA) of the Act, specifically concerning the exclusion of certain drugs and medicinal preparations from the Pharmaceutical Benefits Scheme. The policy objective behind this declaration is to remove Mibefradil Dihydrochloride from the list of subsidised medications, effective from 17 June 1998, following the advice of the Pharmaceutical Benefits Advisory Committee. The enactment of this legislative instrument reflects the ongoing efforts to regulate and refine the Pharmaceutical Benefits Scheme to align with public health needs and safety standards.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations, in this case, Mibefradil Dihydrochloride, which ceases to be covered under Part VII of the Act following this declaration. The Act operates at the Commonwealth level, impacting the Pharmaceutical Benefits Scheme (PBS) administered by the Department of Health. This declaration effectively removes the specified drug from the list of those for which the Commonwealth provides benefits, thereby affecting healthcare providers, patients, and pharmaceutical entities that would otherwise be involved in the supply and reimbursement of the drug under the PBS. There are no stated exclusions, exemptions, or thresholds in this particular declaration, and its application is limited to the cessation of pharmaceutical benefits for the named drug as of the effective date. Subordinate instruments may further extend or restrict the application of the Act, but this declaration itself does not outline such provisions.

Key Provisions

The main operative sections of this Declaration under subsection 85(2AA) of the National Health Act 1953 (section 2) specify that the drugs and medicinal preparations listed in the Schedule will cease to be subject to Part VII of the Act. This means that the specified medications will no longer be covered under the Pharmaceutical Benefits Scheme (PBS). For instance, Mibefradil Dihydrochloride is the only drug listed in the Schedule and, as a result, it will no longer be eligible for the benefits provided under Part VII of the Act. The obligations and requirements imposed by this Act on the relevant parties or entities include obtaining advice from the Pharmaceutical Benefits Advisory Committee, as stated in subsection 85(2AB) of the Act. The advice must be sought prior to making such a declaration, which is demonstrated in this case by the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Family Services, and Delegate of the Minister for Health and Family Services, David Trevor Graham, who obtained the necessary advice before making this declaration. In terms of offences, penalties, or civil/criminal consequences for breach, the Act does not explicitly outline these details within the provided text. However, the failure to comply with the requirements outlined in the Act, such as not obtaining the necessary advice before making a declaration, could result in legal consequences. The maximum penalties for breaches of the National Health Act 1953 may vary depending on the specific offence and circumstances of the breach. For example, penalties for breaches of the Act can range from fines to imprisonment, depending on the severity of the offence. It is important for the relevant parties to adhere to the requirements outlined in the Act to avoid any potential legal consequences.